English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective:  Mutations in TP53 lead to loss of function (LOF) or gain of function (GOF) of the corresponding protein p53 and produce a different effect on the tumor. Our goal was to determine the spectrum of somatic  TP53  variants in  BRCA1/2  associated high-grade serous ovarian cancer (HGSOC).   Methods:  The population under study comprised of HGSOCs with pathogenic variants in  BRCA1  ( n  = 78) or  BRCA2  ( n  = 21). Only chemo-naive and platinum-sensitive patients were included in this study. The case group of the IARC database ( n  = 1249) with HGSOC not stratified by BRCA status was used as a reference. A custom NGS panel was used for sequencing  TP53  and mutational hot-spots of other genes, and p53 expression was evaluated by immunohistochemistry for 68 cases of HGSOCs.   Results:  Somatic  TP53  variants (95) or inhibition of wild-type p53 expression (3) were observed in 98 cases. The sample with normal p53 had  CDKNA1  variants. The frequency of truncating variants was significantly higher than in the reference cohort (30.3 vs. 21.0%,  p  = 0.01). Most of the samples (41/68) demonstrated low (or absent) expression of p53, and 17 samples overexpressed p53. LOH was typical for TP53 nonsense variants (14/15). In total, 68/95 samples were LOH positive and showed LOH in all tumorous cells, thus indicating the driver effect of  TP53  mutations. Three specimens had  KRAS, BAX, APC , and  CTNNB1  subclones variants.   Conclusion:  High frequency of  TP53  truncating variants, the low expression of mutant p53, and low incidence of oncogene mutations show potential GOF properties of p53 to be poorly represented in BRCA1/2 associated HGSOC.

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer